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With a Mistaken Diagnosis of Acute Myocardial Infarction 
JAMES C. BLANKENSHIP, MD, FACC, ADRIAN K. ALMQUIST, MD 
Danville, Pennsylvania and Minneapolis, Minnesota 
Thrombolytic drugs given to patients with a mistaken 
diagnosis of acute myocardial infarction could produce 
adverse effects, although no such cases have been reported. 
Two patients treated with intravenous streptokinase for 
presumed hut nonexistent acute myocardial infarction are 
described. Pericardial tamponade developed in both pa- 
tients, in one after aortic dissection and in the other after 
pericarditis. Both required surgery; one died. 
Symptoms and electrocardiographic abnormalities mim- 
icking acute myocardial infarction may be caused by non- 
coronary syndromes. In such cases, treatment with throm- 
bolytic agents may exacerbate the underlying disease 
process and produce cardiovascular complications. 
(J Am Co11 Cardiol1989;14:1579-82) 
Thrombolytic therapy has become standard treatment for 
selected patients presenting early in the course of acute 
myocardial infarction. Rigorous selection criteria for use of 
thrombolytic therapy may minimize but not totally prevent 
inappropriate use of these drugs. Patients presenting with 
cardiovascular conditions mimicking acute myocardial in- 
farction are at risk for unnecessary bleeding complications 
or catastrophic exacerbation of the underlying condition if 
they are inappropriately treated with thrombolytic agents 
(1,2). This report describes two patients treated with intra- 
venous streptokinase for a mistaken diagnosis of acute 
myocardial infarction who experienced significant cardio- 
vascular complications. 
Case Reports 
Patient 1. A 60 year old man with no previous cardiac 
history presented with the acute onset of severe sharp 
substernal chest pain and dyspnea at rest. A pericardial 
friction rub was present. The electrocardiogram (ECG) (Fig. 
1A) was interpreted by the primary physician as consistent 
with acute anterior myocardial infarction. Echocardiography 
showed a small but abnormal pericardial effusion without 
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features of tamponade; formal interpretation was not imme- 
diately available to the primary physician. intravenous 
streptokinase (1.5 million U) was given over 1 h. Approxi- 
mately 1 h later, hypotension and pulmonary congestion 
developed and the patient was transferred to our medical 
center with a diagnosis of cardiogenic shock. 
On admission, systolic blood pressure was 80 mm Hg, 
heart rate was 120 beatslmin, pulmonary rales were present 
and the neck veins were markedly distended. Heart sounds 
were normal; a rub was not appreciated. Echocardiography 
showed a large pericardial effusion with features of tampon- 
ade, as well as an aortic intimal flap that suggested dissec- 
tion. Emergency pericardiocentesis removed 400 ml of gross 
blood and immediately increased systolic blood pressure to 
120 mm Hg. Computed tomographic scanning showed aortic 
dissection (type I) extending from the aortic root to the 
infrarenal aorta. 
Emergent aortic repair was attempted. Surgery was 
complicated by extensive bleeding requiring 26 units of 
packed red blood cells, 36 units of fresh frozen plasma and 
120 units of cryoglobulin. The patient could not be weaned 
from cardiopulmonary bypass and died without regaining 
consciousness after 13 h in the operating room. A serum 
creatine kinase level measured 11 h after the onset of chest 
pain was normal. Autopsy demonstrated no evidence of 
myocardial infarction or coronary artery thrombosis. 
Patient 2. A 71 year old man with no previous cardiac 
history developed dyspnea and orthopnea over 3 days and 
substernal chest pain on the day of admission. Vital signs 
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Figure 1. Twelve lead electrocardiograms from Patients 1 (A) and 2 strated a very large pericardial effusion with evidence of 
(B) at the time of presentation to the referring hospitals. tamponade. 
were normal. The physical examination was normal. The 
chest X-ray film showed cardiomegaly (cardiothoracic ratio 
0.59). The ECG was interpreted as showing acute anterior 
myocardial infarction (Fig. 1B). The patient was treated with 
intravenous streptokinase (1.5 million units). Because of 
continued chest pain, he was transferred to our medical 
center on the next day. 
On admission, blood pressure was 1 lo/60 mm Hg, with 30 
mm of paradoxic pulse. Heart rate was 90 beats/min and the 
neck veins were markedly distended. Heart sounds were 
diminished and no pericardial friction rub was present. An 
ECG showed diffuse ST elevation consistent with pericardi- 
tis. The chest X-ray film showed increased cardiomegaly 
(cardiothoracic ration 0.66). Echocardiography demon- 
The prothrombin time was elevated at 14.9 s because of 
streptokinase given ~24 h earlier; therefore, pericardial 
drainage was delayed until the next day. A subxiphoid 
pericardial window was created surgically, and 1 liter of 
hemorrhagic fluid was drained. The patient’s postoperative 
course was benign. Serial creatine kinase and MB isoenzyme 
values were normal. 
Discussion 
These two patients experienced a complication related to 
intravenous streptokinase that had been predicted (l-5) but 
not previously reported. In both cases, a primary physician 
diagnosed acute myocardial infarction from the ECG. In 
neither case was the diagnosis confirmed by cardiologists 
blindly interpreting the same ECG. In both cases, subse- 
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quent tests conclusively ruled out acute myocardial infarc- 
tion. In retrospect, symptoms and ECG changes were 
caused by pericardial disease or aortic dissection, or both. In 
both patients, streptokinase may have caused or exacer- 
bated the inappropriate bleeding that produced tamponade 
and hemodynamic compromise. In both patients, hemody- 
namic status worsened and the pericardial effusion enlarged 
after streptokinase was given. Streptokinase complicated 
the surgical management by contributing to excessive bleed- 
ing in Patient 1 and by delaying surgery in Patient 2. In both 
cases, the use of tissue plasminogen activator instead of 
streptokinase might have simplified surgical treatment be- 
cause of the former’s briefer disruption of hemostatic mech- 
anisms. 
Previous reports. Other patients with syndromes mimick- 
ing acute myocardial infarction have been treated with 
intravenous streptokinase without adverse effects. Tilley 
and Harston (1) reported on two patients with acute peri- 
carditis given streptokinase for presumed acute myocardial 
infarction. Both gradually developed nonhemorrhagic tam- 
ponade 2 to 4 days later. The authors (1) did not attribute 
tamponade to thrombolytic therapy, but did point out the 
risk of thrombolytic therapy producing rapid hemorrhagic 
tamponade with catastrophic consequences in patients with 
pericarditis. Ferguson et al. (3) described an additional 
patient receiving streptokinase for pericarditis without ad- 
verse consequences. Satler et al. (2) described three patients 
diagnosed as having acute myocardial infarction and referred 
for intracoronary streptokinase. Emergent coronary arteri- 
ography demonstrated patent coronary arteries, and subse- 
quent investigation revealed aortic dissection. Satler et al. 
(2) pointed out the potential for adverse consequences if 
these patients had been given thrombolytic therapy before 
their true diagnosis was determined. Although none of the 
six patients reported by the authors (l-3) suffered adverse 
consequences from thrombolytic therapy, they demon- 
strated the potential for disaster when thrombolytic therapy 
is given to patients with cardiovascular conditions mimick- 
ing acute myocardial infarction. 
The potential for misdiagnosis of chest pain syndromes. 
The potential is clear. The Gruppo Italian0 per lo Studio 
della Streptochinasi nell’Infarcto Miocardico (GISSI) trial 
(6) documented a 5.8% incidence of incorrect diagnoses of 
acute myocardial infarction. The Anglo-Scandinavian Study 
of Early Thrombolysis (ASSET) (7) found that 4.1% of 
patients with suspected acute myocardial infarction had a 
nonischemic syndrome and another 6.4% had coronary 
disease without acute myocardial infarction. Although 
thrombolytic therapy given to the small fraction of patients 
without myocardial infarction in these studies was not re- 
ported to have adverse effects, it could prove catastrophic in 
individual patients. In ASSET, among patients in whom a 
nonischemic chest pain syndrome was finally diagnosed, 
those treated with tissue plasminogen activator had a 9.5% 
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mortality rate; those treated with placebo had only a 1.2% 
mortality rate. The higher mortality rate in the group treated 
with tissue plasminogen activator may reflect adverse effects 
of thrombolytic therapy in patients similar to ours. 
Implications. Two large recent trials (7,8) demonstrated 
improved survival in patients with suspecred acute myocar- 
dial infarction treated with a thrombolytic drug. In both 
studies, even patients admitted with a normal ECG and 
treated with thrombolytic drugs showed a trend toward a 
decreased mortality rate. However, no study to date has 
shown that thrombolytic drugs decrease the incidence of 
death in patients with chest pain in whom acute myocardial 
infarction is ultimately excluded. Therefore, it is appropriate 
that, at present, most centers require rigid ECG criteria of 
acute myocardial infarction (2 1 mm of ST segment elevation 
in two contiguous leads) before considering a patient for 
thrombolytic therapy. If the diagnosis is unclear after the 
initial ECG, it is important for the physician to clarify it 
before giving thrombolytic therapy. Serial ECGs spaced as 
closely as 20 min apart may reveal evolving diagnostic 
changes. Emergent angiography or echocardiography may 
demonstrate evidence of ischemic disease or diagnose other 
syndromes responsible for chest pain. It is notable that, in 
both of our patients, timely performance and interpretation 
of the two-dimensional echocardiogram might have detected 
the pericardial effusion and prevented the inappropriate use 
of streptokinase. 
Conclusion. The physician must strike a delicate balance 
between offering treatment to those it will help and withhold- 
ing it from those whom it may harm. This report illustrates 
the dangers of initiating thrombolytic therapy before the 
diagnosis is certain. Aggressive, accurate diagnosis of 
patients with acute chest pain and nondiagnostic ECGs 
will help the physician adhere to the caveat “first, do no 
harm.” 
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